7 research outputs found
Anti-PT seroprevalence at T1 in all villages according to age category.
a<p>Chi-square test has been performed.</p>b<p>Kruskal-Wallis test between IgG responses according to the villages.</p>c<p>Mann-Whitney test has been performed for children of the same villages.</p
Seroprevalence of anti-PT IgG concentrations according to the village and visit for children younger (panel A) and older than 3 years (panel B).
<p>Chi-square test between seropositive children (anti-PT IgG concentration >30 IU/ml) and seronegative children at each visit within villages: panel A.: Agniam, <b>p = 0.3588</b>; Fanaye, p = 0.5227; Niandane, p = 0.4056; Pendao, p = 0.4276; Guédé, p = 0.9928; panel B.: Agniam, <b>p<0.0008</b>; Fanaye, p = 0.7641; Niandane, p = 0.2280; Pendao, p = 0.3292; Guédé, p = 0.1754.</p
PT-IgG >30 IU/ml at T1 according to age categories and villages.
<p>Percentages of children with PT-IgG >30 IU/ml at the first visit in every village.</p><p>Total number of children within age category is in brackets.</p
Description of the cohort at the beginning of the survey (T1).
a<p>ANOVA test of age differences between children of all villages, and between ages of children of all villages according to their vaccination status.</p>b<p>Chi-square test to assess the gender distribution among villages and distribution of children within villages according to their vaccination status.</p><p>2 children were not vaccinated, one from Fanaye, and the other from Pendao.</p
PT-IgG responses at T1.
a<p>One-way ANOVA between IgG responses according to villages.</p>b<p>Chi-square test between seroprevalence according to villages.</p
Seroconversion throughout the visits in each village.
<p>Chi-square test between number of seroconverters (sera becoming newly positive to PT) and rest of population from the village.</p